Identifying novel mechanisms and treatment targets for irritability and aggression in psychiatric disorders

Manish Kumar Jha; Madhukar H. Trivedi

doi:10.1038/s41386-021-01166-4

Identifying novel mechanisms and treatment targets for irritability and aggression in psychiatric disorders

Manish Kumar Jha, Madhukar H. Trivedi

Research output: Contribution to journal › Comment/debate

2 Scopus citations

Original language	English
Pages (from-to)	420-421
Number of pages	2
Journal	Neuropsychopharmacology
Volume	47
Issue number	1
DOIs	https://doi.org/10.1038/s41386-021-01166-4
State	Published - Jan 2022

Access to Document

10.1038/s41386-021-01166-4

Cite this

@article{4f11e4e5ff924f3a9595f29eb760a270,

title = "Identifying novel mechanisms and treatment targets for irritability and aggression in psychiatric disorders",

author = "Jha, {Manish Kumar} and Trivedi, {Madhukar H.}",

note = "Funding Information: This work was supported by the Hersh Foundation and the Center for Depression Research and Clinical Care (PI: Madhukar Trivedi) at UT Southwestern. MKJ has received contract research grants from Acadia Pharmaceuticals and Janssen Research & Development, educational grant to serve as Section Editor of the Psychiatry & Behavioral Health Learning Network, consultant fees from Eleusis Therapeutics US, Inc, and honoraria for CME presentations from North American Center for Continuing Medical Education and Global Medical Education. patent for using mTORC1 inhibitors to augment the effects of antidepressants (Aug 20, 2018). MHT has served as an adviser or consultant for Abbott Laboratories, Abdi Ibrahim, Akzo (Organon Pharmaceuticals), Alkermes, AstraZeneca, Axon Advisors, Bristol-Myers Squibb, Cephalon, Cerecor, CME Institute of Physicians, Concert Pharmaceuticals, Eli Lilly, Evotec, Fabre Kramer Pharmaceuticals, Forest Pharmaceuticals, GlaxoSmithKline, Janssen Global Services, Janssen Pharmaceutica Products, Johnson & Johnson PRD, Libby, Lundbeck, Meade Johnson, MedAvante, Medtronic, Merck, Mitsubishi Tanabe Pharma Development America, Naurex, Neuronetics, Otsuka Pharmaceuticals, Pamlab, Parke-Davis Pharmaceuticals, Pfizer, PgxHealth, Phoenix Marketing Solutions, Rexahn Pharmaceuticals, Ridge Diagnostics, Roche Products, Sepracor, Shire Development, Sierra, SK Life and Science, Sunovion, Takeda, Tal Medical/Puretech Venture, Targacept, Transcept, VantagePoint, Vivus, and Wyeth-Ayerst Laboratories; he has received grants or research support from the Agency for Healthcare Research and Quality, Cyberonics, NARSAD, NIDA, and NIMH.",

year = "2022",

month = jan,

doi = "10.1038/s41386-021-01166-4",

language = "English",

volume = "47",

pages = "420--421",

journal = "Neuropsychopharmacology",

issn = "0893-133X",

publisher = "Springer Nature",

number = "1",

}

TY - JOUR

T1 - Identifying novel mechanisms and treatment targets for irritability and aggression in psychiatric disorders

AU - Jha, Manish Kumar

AU - Trivedi, Madhukar H.

N1 - Funding Information: This work was supported by the Hersh Foundation and the Center for Depression Research and Clinical Care (PI: Madhukar Trivedi) at UT Southwestern. MKJ has received contract research grants from Acadia Pharmaceuticals and Janssen Research & Development, educational grant to serve as Section Editor of the Psychiatry & Behavioral Health Learning Network, consultant fees from Eleusis Therapeutics US, Inc, and honoraria for CME presentations from North American Center for Continuing Medical Education and Global Medical Education. patent for using mTORC1 inhibitors to augment the effects of antidepressants (Aug 20, 2018). MHT has served as an adviser or consultant for Abbott Laboratories, Abdi Ibrahim, Akzo (Organon Pharmaceuticals), Alkermes, AstraZeneca, Axon Advisors, Bristol-Myers Squibb, Cephalon, Cerecor, CME Institute of Physicians, Concert Pharmaceuticals, Eli Lilly, Evotec, Fabre Kramer Pharmaceuticals, Forest Pharmaceuticals, GlaxoSmithKline, Janssen Global Services, Janssen Pharmaceutica Products, Johnson & Johnson PRD, Libby, Lundbeck, Meade Johnson, MedAvante, Medtronic, Merck, Mitsubishi Tanabe Pharma Development America, Naurex, Neuronetics, Otsuka Pharmaceuticals, Pamlab, Parke-Davis Pharmaceuticals, Pfizer, PgxHealth, Phoenix Marketing Solutions, Rexahn Pharmaceuticals, Ridge Diagnostics, Roche Products, Sepracor, Shire Development, Sierra, SK Life and Science, Sunovion, Takeda, Tal Medical/Puretech Venture, Targacept, Transcept, VantagePoint, Vivus, and Wyeth-Ayerst Laboratories; he has received grants or research support from the Agency for Healthcare Research and Quality, Cyberonics, NARSAD, NIDA, and NIMH.

PY - 2022/1

Y1 - 2022/1

UR - http://www.scopus.com/inward/record.url?scp=85119965084&partnerID=8YFLogxK

U2 - 10.1038/s41386-021-01166-4

DO - 10.1038/s41386-021-01166-4

M3 - Comment/debate

C2 - 34545193

AN - SCOPUS:85119965084

SN - 0893-133X

VL - 47

SP - 420

EP - 421

JO - Neuropsychopharmacology

JF - Neuropsychopharmacology

IS - 1

ER -